Petros Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals

(please see important safety information below) new york, ny / accesswire / april 16, 2024 / petros pharmaceuticals, inc. ("petros," or the "company") (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces it has received positive feedback from the u.s. food and drug administration (the "fda," or the "agency") following the fda's informal review of petros' technology component for self-selection as the company endeavors to achieve otc status for stendra. the agency acknowledged that the technology addressed some of its concerns regarding the pde5 inhibitor class in that context, particularly with regard to nitrate-using patients.

Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential benefits of technology assistance in an otc setting (please see important safety information below) new york, ny / accesswire / april 2, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces positive results of an initial cohort of its self-selection study comparing the use of a drug facts label (dfl) alone to a dfl in combination with a web app (technology component).

Petros begins enrollment in ai integrated human factors study to optimize self-screening, continuing its efforts to make stendra (avanafil) the first erectile dysfunction medication to achieve otc status (please see important safety information below) new york, ny / accesswire / march 19, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces it has successfully launched its artificial intelligence (ai) tool developed as a result of its collaboration with a multi-billion-dollar software developer. the tool is being integrated into the company's web app being used for patient self-screening, which it is testing in its recently launched human factors study.

Ai software expected to further enable petros's efforts to make stendra the first ed product to be offered over the counter new york, ny / accesswire / february 14, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces a new partnership with a leading, multi-billion-dollar ai software provider to adapt its technology for self-screening and other benefits as part of the company's ongoing efforts to bring stendra over the counter. the technology will be integrated into the core tool the company has already developed as part of its self-selection study, which is currently underway.

Fda requests meeting to review the company's technology component and discuss further development and requirements new york, ny / accesswire / january 24, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces it has scheduled two meetings with the u.s. food and drug administration (fda) to review the company's progress and path forward in developing stendra as the first pde-5 inhibitor approved as an over-the-counter medication for erectile dysfunction. (please see important safety information below.

NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.

Use these top charts to profit with penny stocks The post Top Penny Stocks Chart Patterns to Use to Profit  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Use these tips for researching penny stocks in 2023 The post Penny Stock Due Diligence: Top Research Techniques  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Investing in energy penny stocks? Here's some top tips The post Buying Energy Penny Stocks?

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present virtually at the Planet MicroCap Showcase 2022. The conference is being held on May 3 – 5, 2022 at The Bally's Hotel & Casino in Las Vegas, NV.

Can these penny stocks climb this coming week? The post 3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are these strategies on your list for buying penny stocks next month? The post Best Penny Stocks, How To Buy & Strategies for Beginners appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q1 Investor Summit Conference, which is being held virtually on March 8 – 9, 2022.

Are short squeeze penny stocks part of your strategy this week? The post Best Penny Stocks To Buy This Week?